Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

The financing round will fund the improvement of the company’s technology platform for the discovery and development of ...

Genesis Therapeutics has secured $200 million funding from NVentures, NVIDIA’s venture capital arm. This forms part of an expanded partnership to enhance Genesis’ AI-powered drug discovery platform, ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Driven by the effects of the COVID-19 pandemic, the market for decentralized clinical trials has seen a push that will lead ...

Gifthealth has announced a strategic partnership with United Digestive, a leading practice management organization for ...

Pharmacokinetic (PK) tests form an integral part of the drug development process, helping to ensure the safety and efficacy ...

While these sites are important for clinical research, they make patient recruitment challenging. Many participants are ...

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

A recent Lindus Health survey emphasizes the importance of patient-centered designs in clinical trials, particularly ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial ...